KG LEGAL \ INFO
BLOG

15 new medical professions in Poland – from March 26, 2024

Publication date: April 15, 2024

15 new medical professions in Poland – the new act of law entered into force on March 26, 2024. Importantly, work is still underway on the regulation specifying professional activities for individual medical professions, and this is important in the context of employers entrusting the scope of responsibilities to persons performing these new medical professions, such as also the need to ensure the health safety of patients.

New medical professions in Poland – from March 26, 2024.

More

PLANNED AMENDMENTS TO ABORTION LAW IN POLAND – CONTROVERSIES

Publication date: April 15, 2024

The issue of the right to abortion in Poland is currently a lively topic of political discussions aimed at changing existing regulations in a way that gives women the right to decide about their own body. Currently, attention is focused on four projects (drafts) bringing changes in the analyzed topics:

More

PATIENT ENGAGEMENT WITH AI

Publication date: April 05, 2024

Conversational AI and AI powered video bots for health education

On March 19th 2024 the lawyers of KIELTYKA GLADKOWSKI took part in the workshop devoted to the use of AI in patient engagement.

The workshop focused on the utilization of artificial intelligence (AI) in patient care and was led by Lawrence Byrd, Senior Director of Communications APIs at Vonage. The Vonage company is a global cloud communication leader providing Apps and APIs (such as AI, Video, Voice, SMS, UC, and more) and is a prominent supplier of embedded video for hundreds of global Telehealth innovators. Vonage also assists businesses in stimulating their digital transformation.

More

Is it worth conducting clinical trials of modern drugs and devices in the European Union? Is the EU attractive for investment compared to other parts of the world?

Publication date: April 03, 2024

The sale of a new drug or medical device and clinical trials is a process between two opposing interest groups. On the one hand, it is about patient protection and the safety of the pharmaceutical market. On the other hand, it is about creating a legal environment that will accelerate the creation of new drugs.

Both goals are important. It is important to create the right legal balance. The balance between patient protection and facilitation of modern medicines and medical devices makes Europe attractive for locating new innovations in technology and creating new medicines and medical devices.

Placing legal priorities in creating law is a political compromise between the speed of producing a new drug and blocking innovation justified by patient safety.

The attractiveness of Europe for the pharmaceutical business compared to other global markets depends on the proper placement of priorities.

More

Liability for damages incurred in connection with conducting a clinical trial – EU and Polish law

Publication date: February 27, 2024

Conducting a clinical trial does not relieve the investigator and sponsor from civil liability arising from the clinical trial, under Polish law provisions. The sponsor and the investigator are civilly liable for any damage caused to a clinical trial participant resulting from their actions or omissions. The above general principles of liability for damage arising in connection with conducting a clinical trial create a legal mechanism of liability and illegality of the act under the Polish Act of March 9, 2023 on clinical trials of medicinal products for human use (Journal of Laws, item 605).

More

UP